Outcomes with guideline-directed medical therapy and cardiac implantable electronic device therapies for patients with heart failure with reduced ejection fraction - Heart Rhythm O2 heartrhythmopen.com/article/S2666-…

📰📢 egnite has been named to Fast Company #FCMostInnovative Companies of 2024. This was possible due to the tireless work of every egniter, whose commitment helps us maintain our position as a leader in the #digitalhealth space. Read more: ow.ly/7MhH50QWBoY

Congratulations to Philippe Genereux 👏 His AS mortality study was selected as 1️⃣ of only 7️⃣ publications in valvular heart disease to be selected as JACC Journals Editor in Chief's top 100 notable publications of 2023! ow.ly/MunC50R1obA #AorticStenosis #Cardiology

We are honored to welcome two distinguished physicians 👨‍⚕️, Vinod Thourani & NickAmorosoMD, to egnite's Medical Advisory Board. Their wealth of expertise will provide significant contributions to our mission to improve cardiovascular care nationwide. 🫀 ow.ly/VFrk50R1pVj

We're excited to see you in Atlanta for #ACC24 next week! Leading cardiovascular programs are partnering with egnite to advance their practice. Connect with us in the Future Hub to learn more about partnership. ow.ly/Y59O50R1q86 #DigitalHealth #Cardiology

Join us and JenaValve Technology at #ACC24 as Philippe Genereux unveils novel research on the mortality burden for patients with untreated aortic regurgitation! ow.ly/UNo050R69Rg #AorticRegurgitation #Cardiology #Research

Congrats to Philippe Genereux and JenaValve Technology on this important research in aortic regurgitation (AR) finding similar high mortality risk for some patients with untreated moderate AR with key markers of cardiac damage and those with untreated severe AR. ow.ly/4s8750R9Rqa

Clinicians 👩‍⚕️ often end up in business-related roles within the health system 🏥 that require different skillsets. Informative dashboards 📊 can help lead to better decision making & the opportunity to make compelling cases for additional resources. ow.ly/Zufy50RbunC

How are you proactively managing your cardiovascular patient population? The CardioCare platform identifies patients in your system who are eligible for guideline-directed therapy, but have not seen a specialist for evaluation. 👩‍⚕️👨‍⚕️ ow.ly/Ok0I50RikBp #DigitalHealth

Egnite’s CardioCare platform is expanding the boundaries of cardiovascular medicine f-st.co/ke30DBD

In just 6 months, the CardioCare platform helped to identify and navigate 36 patients through to a life-saving treatment. 🏥 Learn more about Altru Health System's experience with the CardioCare platform: egnitehealth.com/wp-content/upl… #DigitalHealth #SavingLives #Cardiology

As the #DigitalHealth industry continues to grow, egnite is leading innovation in #Cardiology patient management & data analytics. We are honored to have been named to Newsweek and Statista list of World’s Best Digital Health Companies for 2024!🏅 ow.ly/VwVp50Rpn7L

Recent FDA approval of TriClip provides more great options for patients in the US with tricuspid regurgitation! 👏 ow.ly/YsLJ50RtElz #TricuspidRegurgitation #Cardiology

"In heart failure, data is your friend. It gives us benchmarks, helps identify patients for outreach, and allows us to proactively manage this population..." Lauren Lindner and Dr. Shane LaRue speak to their experience at St. Luke's Hospital with the CardioCare platform. #HeartFailure

👏 to John Mignone, Kevin Alexander, Gregg Fonarow MD, Kenneth Ellenbogen on their recently published manuscript in Heart Rhythm O2. These insights demonstrate real-world trends in HF care & further suggest the benefits of combined device therapy & contemporary GDMT. ow.ly/ABWJ50RC9mP

egnite Kevin Alexander Kenneth Ellenbogen Heart Rhythm O2 43,591 patients with HF from 24 US health systems Quad GDMT use for HFrEF in only 8.8% of eligible patients Even with additional 24 months f/u, quad GDMT used in only 17.2% Quad GDMT use associated with 58% lower ☠️ risk over 24 months

We're excited to see new medical therapy options 💊 for hypertrophic cardiomyopathy with class 1 recommendations in the newly released 2024 guidelines for management. ow.ly/iK1X50RGmT2 #Cardiology

A mid-sized #HealthSystem 🏥 used the CardioCare platform to establish their #Cardiovascular 🫀 program as a referral destination for high-quality care, identifying & navigating 43 patients across VHD, HF, & AF through to an intervention in just 7 months. ow.ly/nc7B50RC2oO

"We purchased the ‘best’ version of our EMR, & when we utilized the original criteria, we identified few possible LAAC candidates, whereas your software helped to identify many good candidates." Chat with us to learn how we can help you find the right patients at the right time.

Oh no! 😱 Another week has gone by and 1848 preventable ☠️s of individuals with HF in the US likely occurred These could have been avoided with optimal implementation of quadruple GDMT for HFrEF ✅ 🎯 Class 1 in guidelines ARNI+BB+MRA+SGLTi ✅ 💵 Cost-effective Next week?